Clinical study to evaluate the efficacy and safety of darbepoetin-alfa in kidney transplant recipients with erythropoietin-resistant anemia

Clinical study to evaluate the efficacy and safety of darbepoetin-alfa in kidney transplant recipients with erythropoietin-resistant anemia - Darbepoetin-alfa for erythropoietin-resistant post transplant anemia

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006661

Enrollment

Registered

2011-12-01

Start date

2011-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post-transplantation anemia

Interventions

Darbepoetin-alfa for 6-12 months

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Kidney transplant patients 2.Patients who have continued EPO treatment for more than three months 3.Patients who have hemoglobin <11g/dL in spite of EPO treatment

Exclusion criteria

Exclusion criteria: 1.Patients with active infection or malignancy 2.Patients who receive surgical management

Design outcomes

Primary

Measure	Time frame
1.Mean hemoglobin level at the end of the study. 2.Percentage of patients with hemoglobin level within the target range of 11 to 13 g/dL at the end of the study	—

Secondary

Measure	Time frame
1.Dose of darbepoetin-alfa 2.Changes in estimated glomerular filtration rate 3.Changes in blood pressure	—

Countries

Japan

Contacts

Public ContactKakuta Yoichi

Osaka University Graduate School of Medicine Department of Specific Organ Regulation (Urology)

kakuta@uro.med.osaka-u.ac.jp06-6879-3531

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026